County Armagh headquartered Almac Group has climbed three positions to number five in this year’s Ulster Business “Most valuable businesses” table.
The global contract development and manufacturing organisation, that provides services across the drug development lifecycle to the pharmaceutical and biotech sectors, also moved from tenth to eighth in the supplementary list of “most profitable companies in Northern Ireland”.
Almac is currently supporting over 80 separate research programs to accelerate COVID-19 treatment.
The Craigavon based firm’s services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
“We are delighted to see Almac placed at number five in this year’s Ulster Business Top 100 companies tables,” commented Almac Group’s Finance Director, Niall Harkin.
“2019 was a highly successful year for Almac as we continued to invest significantly in our people, facilities and unique solutions to ensure our growing client base are offered the most flexible, innovative and efficient services in our marketplace with the sole aim of advancing the health of patients across the world.
“Achieving recognition in these listings, and indeed our overall success, is testament to the dedication, expertise and contribution of our ever increasing global and diverse employee base.”
The news comes as the company’s figures for year ending 30 September 2019 reported a £85.4 million rise in turnover at £634.3 million with pre-tax profits recorded at £47.6 million, up from £27.6 million, while average global employee figures increased from 4,798 to 5,150 during the same period.